NCT07052058View on ClinicalTrials.gov

Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

July 29, 2029

Study Completion Date

July 29, 2029

Conditions
Treatment-Resistant Major Depressive Disorder
Interventions
BIOLOGICAL

Tocilizumab

Single infusion tocilizumab, 8 mg/kg, diluted in 100 mL of normal saline

DRUG

Normal Saline (0.9% NaCl)

Placebo, same volume as intervention

Trial Locations (1)

Unknown

Hospital de Clínicas de Porto Alegre, Porto Alegre

All Listed Sponsors
lead

Hospital de Clinicas de Porto Alegre

OTHER